Three finalists named for the EUROPEAN BIOTECHNICA AWARD 2006

BIOTECHNICAThe three finalists of the EUROPEAN BIOTECHNICA AWARD 2006 have been announced. The international jury of nine experts has nominated biotechnology companies from Germany, Austria and Denmark for the Award, which is worth a total of 40,000 euros in prize money. The jury selected the finalists from a field of 16 outstanding candidates from eight countries.

The following companies – listed below in alphabetical order – will be travelling to Zurich for the grand finale on 12 October 2006:

  • amaxa GmbH, Cologne/Germany
    Founded in 1998, the biotech company amaxa develops and markets innovative products for non-viral gene transfer, enabling researchers to efficiently deliver DNA or siRNA into cells to elucidate the function of genes. amaxa currently employs a workforce of 145 and generated sales of 16.6 million euros in 2005. In addition to its headquarters in Cologne, amaxa also operates a facility in Gaithersburg/USA.
  • Genmab A/S, Copenhagen/Denmark
    The Danish biotech company Genmab specializes in the production and development of human antibodies for the treatment of life-threatening and debilitating cancers and infectious diseases. Employing a staff of 220, the company reported sales of 13.2 million euros in 2005. In addition to its main production facility in Copenhagen, Genmab also has operations in Utrecht/Netherlands, Hitchin/UK and Princeton/USA.
  • Intercell AG, Vienna/Austria
    Founded in Vienna in 1998, Intercell is a biotechnology company focused on the development of innovative vaccines for the prevention and treatment of infectious diseases. The company currently employs 160 people, and posted sales of 8.5 million euros in 2005. Intercell also has a manufacturing facility in Livingston/Scotland and a business development unit in Mooresville/USA.

The award ceremony for the EUROPEAN BIOTECHNICA AWARD 2006 takes place on 12 October 2006. The proceedings begin at 5.30 p.m., immediately following the Biotech CEO Conference hosted by the German Stock Exchange and DZ BANK AG in the Park Hyatt Hotel in Zurich.

Before the official presentation of prizes a series of distinguished speakers will take to the podium to talk about future directions in biotechnology and the life sciences. The line-up is as follows: Dr. Annette Schavan, Federal Minister for Education and Research, Berlin; Dr. Peter Hug, a member of the Executive Committee of F. Hoffmann-La Roche AG, Basel; Jörn Aldag, Chairman of the Board of Evotec AG, Hamburg; and Dr. Hans-Jürgen Leuchs, a member of the Board of Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim. The jury chairman Prof. Dr. Peter Stadler will then deliver the eulogy and present the prizes to the winners of the EUROPEAN BIOTECHNICA AWARD 2006.

"The EUROPEAN BIOTECHNICA AWARD is Europe's most important and valuable prize for small and medium-sized enterprises working in biotechnology and the life sciences," explains Stephan Ph. Kühne, a member of the Board at Deutsche Messe AG in Hannover, which organizes the annual Award. "With the prize award ceremony, talks by guest speakers and an informal get-together for all participants, the event creates the perfect business platform for biotech professionals to network and make valuable contacts," Kühne adds.

The event package accompanying the presentation of the 4th EUROPEAN BIOTECHNICA AWARD highlights the latest industry trends emerging from the collaboration between the major pharmaceutical players and innovative biotechnology companies. "The keynote addresses are sure to stimulate plenty of lively debate at the informal get-together afterwards," Kühne predicts.

One of the chief aims underlying the annual EUROPEAN BIOTECHNICA AWARD and the biennial international trade fair BIOTECHNICA is to promote the formation of effective biotech networks. The next BIOTECHNICA show will take place from 9 to 11 October 2007, when business enterprises and research organizations working in this field will meet again in Hannover to share information and compare notes.

Your contact for further information:
Inga Waldeck
Tel.: +49 (0) 511/89-3 10 26
Fax: +49 (0) 511/89-3 96 95
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

For further information, please visit:
www.biotechnica.de

Most Popular Now

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...

AI Medical Receptionist Modernizing Doct…

A virtual medical receptionist named "Cassie," developed through research at Texas A&M University, is transforming the way patients interact with health care providers. Cassie is a digital-human assistant created by Humanate...

Using Data and AI to Create Better Healt…

Academic medical centers could transform patient care by adopting principles from learning health systems principles, according to researchers from Weill Cornell Medicine and the University of California, San Diego. In...

AI Tool Set to Transform Characterisatio…

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within...

AI Detects Hidden Heart Disease Using Ex…

Mass General Brigham researchers have developed a new AI tool in collaboration with the United States Department of Veterans Affairs (VA) to probe through previously collected CT scans and identify...

Highland Marketing Announced as Official…

Highland Marketing has been named, for the second year running, the official communications partner for HETT Show 2025, the UK's leading digital health conference and exhibition. Taking place 7-8 October...

Human-AI Collectives Make the Most Accur…

Diagnostic errors are among the most serious problems in everyday medical practice. AI systems - especially large language models (LLMs) like ChatGPT-4, Gemini, or Claude 3 - offer new ways...

MHP-Net: A Revolutionary AI Model for Ac…

Liver cancer is the sixth most common cancer globally and a leading cause of cancer-related deaths. Accurate segmentation of liver tumors is a crucial step for the management of the...